Phase 3Active, not recruiting
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients With Chronic Hepatitis B Infection
- Sponsor
- Gilead Sciences (Industry)
- Enrollment
- 90 enrolled
- Conditions
- Chronic Hepatitis B
- Interventions
- Tenofovir DF; TDF Placebo
- Ages
- children
- Registry
- NCT01651403, CTIS2024-517526-26-00, EUCTR2012-000586-20
Full record on ClinicalTrials.gov
From the registry
The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to \< 12 years at the time of enrollment) with chronic hepatitis B (CHB) infection.
Primary outcomes
- Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Failure Approach)
- Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Excluded Approach)
History
Study completion expected
Last registry update
Results first posted
Primary completion
Started
Registered